Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | ADH5 | P11766 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24881275 | 0.79 | NR1H2 (0.42) | ALDH1A1USP30NAMPT | |
| SCHEMBL31700808 | 0.77 | PTPN2 (0.43) | ALDH1A1USP30NAMPT | |
| SCHEMBL31510781 | 0.76 | GPR119 (0.47) | ALDH1A1 | |
| SCHEMBL29197802 | 0.75 | ALDH1A1 (0.52) | ALDH1A1NAMPT | |
| SCHEMBL30273513 | 0.74 | PGR (0.39) | SCD5 | |
| SCHEMBL31342735 | 0.74 | MEN1 (0.39) | SCD5HDAC4USP30NAMPT | |
| SCHEMBL31510798 | 0.73 | GPR119 (0.48) | USP30 | |
| SCHEMBL31510694 | 0.73 | GPR119 (0.38) | HDAC4USP30NAMPT | |
| SCHEMBL31510725 | 0.73 | GPR119 (0.44) | USP30 | |
| SCHEMBL31342565 | 0.72 | HDAC2 (0.36) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025066935-A1 | COMPOUNDS, COMPOSITIONS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | WO | disclosed |